Cargando…

Combination targeted and immune therapy in the treatment of advanced melanoma: a valid treatment option for patients?

Melanomas harboring an activating BRAFV600 mutation account for 50% of all advanced melanomas. The approval of BRAF-targeted therapy revolutionized treatment of these patients with achievement of impressive responses. However, development of resistance to these drugs is a significant problem, and as...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bari, Shahla, Muzaffar, Jameel, Eroglu, Zeynep
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9036333/ https://www.ncbi.nlm.nih.gov/pubmed/35478991 http://dx.doi.org/10.1177/17588359221090306

Ejemplares similares

Recent Advances and Future Directions in Clinical Management of Head and Neck Squamous Cell Carcinoma
por: Muzaffar, Jameel, et al.
Publicado: (2021)

Encorafenib/binimetinib for the treatment of BRAF-mutant advanced, unresectable, or metastatic melanoma: design, development, and potential place in therapy
por: Sun, James, et al.
Publicado: (2018)

The emergence of neoadjuvant therapy in advanced melanoma
por: Sun, James, et al.
Publicado: (2019)

Awareness, Use and Outlook of Complementary and Alternative Medicine (CAM) Options in an Underserved, Uninsured Minority Cancer Patient Population
por: Bari, Shahla, et al.
Publicado: (2021)

Combining targeted therapy and immune checkpoint inhibitors in the treatment of metastatic melanoma
por: Kim, Teresa, et al.
Publicado: (2014)

Combined targeted therapy and immunotherapy in the treatment of advanced melanoma
por: Wilmott, James S., et al.
Publicado: (2012)

Stereotactic body radiation therapy for the treatment of oligoprogression on androgen receptor targeted therapy in castration-resistant prostate cancer
por: Nguyen, Thu-Cuc, et al.
Publicado: (2018)

Immune Checkpoint Inhibitors and RAS–ERK Pathway-Targeted Drugs as Combined Therapy for the Treatment of Melanoma
por: Morante, Marta, et al.
Publicado: (2022)

Outcomes of Programmed Cell Death Protein 1 (PD-1) and Programmed Death-Ligand 1(PD-L1) Inhibitor Therapy in HIV Patients with Advanced Cancer
por: Bari, Shahla, et al.
Publicado: (2019)

Corrigendum to “Outcomes of Programmed Cell Death Protein 1 (PD-1) and Programmed Death-Ligand 1 (PD-L1) Inhibitor Therapy in HIV Patients with Advanced Cancer”
por: Bari, Shahla, et al.
Publicado: (2019)

MEK inhibitors and their potential in the treatment of advanced melanoma: the advantages of combination therapy
por: Tran, Khiem A, et al.
Publicado: (2015)

Accommodative Insufficiency: Prevalence, Impact and Treatment Options
por: Hussaindeen, Jameel Rizwana, et al.
Publicado: (2020)

Current and emerging treatment options for uveal melanoma
por: Pereira, Patricia Rusa, et al.
Publicado: (2013)

Emerging options for the treatment of melanoma – focus on ipilimumab
por: Roddie, Claire, et al.
Publicado: (2014)

Combination Therapies for the Treatment of Advanced Melanoma: A Review of Current Evidence
por: Voskoboynik, Mark, et al.
Publicado: (2014)

Treatment of Metastatic Melanoma with a Combination of Immunotherapies and Molecularly Targeted Therapies
por: Rager, Taylor, et al.
Publicado: (2022)

Immunotherapy for Melanoma: The Significance of Immune Checkpoint Inhibitors for the Treatment of Advanced Melanoma
por: Fujimura, Taku, et al.
Publicado: (2022)

Targeting Protein Kinases and Epigenetic Control as Combinatorial Therapy Options for Advanced Prostate Cancer Treatment
por: Bagheri, Soghra, et al.
Publicado: (2022)

Uveal melanoma diagnosis and current treatment options (Review)
por: Branisteanu, Daniel Constantin, et al.
Publicado: (2021)

Combination of immunotherapy and other targeted therapies in advanced cutaneous melanoma
por: Marconcini, Riccardo, et al.
Publicado: (2021)

Novel Approaches to Treatment of Advanced Melanoma: A Review on Targeted Therapy and Immunotherapy
por: Niezgoda, Anna, et al.
Publicado: (2015)

Editorial on Special Issue “Advances and Novel Treatment Options in Metastatic Melanoma”
por: Carè, Alessandra, et al.
Publicado: (2022)

Combination treatment including targeted therapy for advanced hepatocellular carcinoma
por: Lin, Jianzhen, et al.
Publicado: (2016)

Nonalcoholic steatohepatitis: emerging targeted therapies to optimize treatment options
por: Milic, Sandra, et al.
Publicado: (2015)

Minimally Invasive Treatment Options for Hepatic Uveal Melanoma Metastases
por: Sajan, Abin, et al.
Publicado: (2023)

Cost-effectiveness of immune checkpoint inhibition and targeted treatment in combination as adjuvant treatment of patient with BRAF-mutant advanced melanoma
por: Li, Si Ni, et al.
Publicado: (2023)

Novel Drugs and Combination Therapies for the Treatment of Metastatic Melanoma
por: Vennepureddy, Adarsh, et al.
Publicado: (2016)

Malignant melanoma in a grey horse: case presentation and review of equine melanoma treatment options
por: Metcalfe, Lucy VA, et al.
Publicado: (2013)

Targeting GPCRs and Their Signaling as a Therapeutic Option in Melanoma
por: Raymond, Jérémy H., et al.
Publicado: (2022)

Advances in targeted therapy and immunotherapy for melanoma (Review)
por: Qin, Ziyao, et al.
Publicado: (2023)

Advances in the pharmaceutical treatment options for canine osteoarthritis
por: Pye, C., et al.
Publicado: (2022)

Pancreatic cancer: optimizing treatment options, new, and emerging targeted therapies
por: Chiorean, Elena Gabriela, et al.
Publicado: (2015)

Molecular Targeted Therapy in Myelodysplastic Syndromes: New Options for Tailored Treatments
por: Pagliuca, Simona, et al.
Publicado: (2021)

Combined Vaccination with B Cell Peptides Targeting Her-2/neu and Immune Checkpoints as Emerging Treatment Option in Cancer
por: Tobias, Joshua, et al.
Publicado: (2022)

Metastatic disease from uveal melanoma: treatment options and future prospects
por: Carvajal, Richard D, et al.
Publicado: (2017)

Malignant Melanoma of the Gastrointestinal Tract: Symptoms, Diagnosis, and Current Treatment Options
por: Kohoutova, Darina, et al.
Publicado: (2021)

Treatment of Advanced Metastatic Melanoma
por: Quaglino, Pietro, et al.
Publicado: (2021)

Targeted Radiation and Immune Therapies—Advances and Opportunities for the Treatment of Prostate Cancer
por: Muralidhar, Anusha, et al.
Publicado: (2023)

Combined Treatments with Photodynamic Therapy for Non-Melanoma Skin Cancer
por: Lucena, Silvia Rocío, et al.
Publicado: (2015)

Combining Targeted Radionuclide Therapy and Immune Checkpoint Inhibition for Cancer Treatment
por: Kleinendorst, Simone C., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_99lb9k61i1amo4qfr32f071av3